Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists

Abstract

The present invention relates to the treatment of dementia and neurodegenerative diseases like Alzheimer's disease with intermediate doses of LHRH antagonists which do not cause a castration. A preferred LHRH antagonist is cetrorelix.

Claims

We claim: 1 . A method of treating one or more of dementia and neurodegenerative diseases in humans comprising the administration of an effective dose of a LHRH antagonist. 2 . The method of claim 1 , wherein said dose is from about 10 to about 100 mg. 3 . The method of claim 1 , wherein said dose is from about 30 to about 60 mg. 4 . The method of claim 1 , wherein the administration is continued for a month, two months or several months. 5 . The method of claim 1 , wherein said disease is Alzheimer's disease. 6 . The method of claim 1 , wherein said LHRH antagonist is cetrorelix. 7 . The method of claim 1 , wherein said LHRH antagonist is teverelix. 8 . The method of claim 1 , wherein said LHRH antagonist is antide. 9 . The method of claim 1 , wherein said LHRH antagonist is abarelix. 10 . The method of claim 1 , wherein said LHRH antagonist is D-63 153. 11 . The method of claim 10 , wherein D-63 153 is Ac-D-Nal-D-p-Cl-Phe-D-Pal-Ser-N-Me-Tyr-D-Hci-Nle-Arg-Pro-D-Ala-NH 2 . 12 . The method of claim 1 , wherein said LHRH antagonist is a peptidomimetic. 13 . The method of claim 12 , wherein said peptidomimetic is selected from: 1-[7-Chloro-3-(3,5-dimethyl-phenyl)-2-oxo-4-(2-piperidin-2-yl-ethoxy)-1,2-dihydro-quinolin-6-yl]-3-pyridin-2-yl-urea; 3-[Benzyl-methyl-amino)-methyl]-2-tert-butyl-8-(2-fluoro-benzyl)-6-(3-methoxyphenyl)-7-methyl-8H-imidazo[1,2-a]pyrimidin-5-one; 2-(2,5-Dimethyl-furan-3-yl)-8-(2-fluoro-benzyl)-3-([methyl-(2-pyridin-2-yl-ethyl)-amino]-methyl)-5-oxo-5,8-dihydro-imidazo[1,2-a]pyrimidine-6-carboxylic acid 1-ethyl-propylester; and 3-((2-[2-(3,5-Difluoro-phenyl)-1-(2-methoxy-benzoyl)-2-oxo-ethylidene]-2,3dihydro-1H-benzoimidazol-5-yl-amino)-methyl)-benzonitrile.
[0001] This application claims the benefit of U.S. Provisional Application No. 60/287,434 filed on Apr. 30, 2001. FIELD OF INVENTION [0002] The present invention relates to the treatment of dementia and neurodegenerative diseases. BACKGROUND OF THE INVENTION [0003] Furuya, Shuichi et al. teach preventives and remedies for Alzheimer's disease containing a GnRH antagonist for preventing and treating Alzheimer's disease with little toxicity in WO 01/78780. SUMMARY OF THE INVENTION [0004] The present invention relates to the treatment of dementia and neurodegenerative diseases with an effective dose of LHRH antagonists. DETAILED DESCRIPTION OF THE INVENTION [0005] It has been shown in a study by Bowen R. L et al. that serum concentrations of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were significantly higher in individuals suffering from dementia, e.g. Alzheimer's disease. Bowen R. L. et al. proposed to lower FSH and LH to minimal levels by the use of high doses of LH-releasing hormone (LHRH) analogues which are either super-agonists or antagonists (CA 2,309,395, US priority Jun. 4, 1999, Ser. No. 09/326,180) of LHRH. This treatment would be accompanied by highly undesirable side effects such as the lowering of sex hormone levels to levels that result in chemical castration, e.g., loss or reduction of libido, sexual desire and sexual potency. In men and pre-menopausal women this treatment would also result in the typical symptoms of decreased levels of sex hormones such as hot flashes, etc. Women would additionally suffer from loss of bone minerals that would limit the usefulness of the treatment. These side effects could be reduced by hormone replacement therapy. [0006] It has now been discovered that treatment with intermediate doses of LHRH antagonists will result in a sub-maximal lowering of FSH and LH levels to normal levels that leave sex hormone levels above the chemical castration threshold. This treatment is highly advantageous as it gives the desired results of normalizing FSH and LH levels without the undesirable side-effects of sex hormone inhibition. Thus the additional treatment with sex hormone replacement therapy becomes superfluous. [0007] The present invention relates to the treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists, wherein the antagonist is preferably cetrorelix, teverelix, antide or abarelix. The antagonist can also be the LHRH antagonist D-63 153 (Ac-D-Nal-D-p-Cl-Phe-D-Pal-Ser-N-Me-Tyr-D-Hci-Nle-Arg-Pro-D-Ala-NH 2 ) as described in the PCT application WO 00/55190 A1, where Nal is 2-napthylalanine, p-Cl-Phe is p-chlorophenylalanine, Pal is 3-pyridylalanine, Hci is homocitrulline and Nle is norleucine. [0008] The mentioned LHRH antagonists can also exhibit a heterocyclic skeletal structure. Such peptidomimetics can be for example: [0009] 1-[7-Chloro-3-(3,5-dimethyl-phenyl)-2-oxo-4-(2-piperidin-2-yl-ethoxy)-1,2-dihydro-quinolin-6-yl]-3-pyridin-2-yl-urea (described in WO 97/44339), [0010] 3-[Benzyl-methyl-amino)-methyl]-2-tert-butyl-8-(2-fluoro-benzyl)-6-(3-methoxy-phenyl)-7-methyl-8H-imidazo[1,2-a]pyrimidin-5-one (described in WO 01/29044), [0011] 2-(2,5-Dimethyl-furan-3-yl)-8-(2-fluoro-benzyl)-3-([methyl-(2-pyridin-2-yl-ethyl)-amino]-methyl)-5-oxo-5,8-dihydro-imidazo[1,2-a]pyrimidine-6-carboxylic acid 1-ethyl-propylester (described in WO 00/69859), [0012] 3-((2-[2-(3,5-Difluoro-phenyl)-1-(2-methoxy-benzoyl)-2-oxo-ethylidene]-2,3-dihydro-1H-benzoimidazol-5-yl-amino)-methyl)-benzonitrile (described in WO 02/02533). [0013] An effective dose of the LHRH antagonist is given in a monthly dose of 10 to 100 mg and the treatment is administered for one month, two months or for several months. An effective dose is defined herein as a dose that is sufficiently limited as to not cause chemical castration. [0014] In a preferred embodiment the LHRH antagonist is given in a monthly dose of 30 to 60 mg and the treatment is administered for one month, two months or for several months. [0015] Pharmaceutical formulations of the LHRH antagonist suitable for the therapeutic management of dementia and neurodegenerative diseases may be for example: [0016] a) acetate salt formulations of the active compounds in concentrations of 1 mg/1 mL or lower where the lyophilized powder may be dissolved in water or in gluconic acid for injection; [0017] b) acetate salt formulations of the active compounds in concentration of 1.5 mg/1 mL to 5.0 mg/1 mL, preferably 2.5 mg/1 mL, where the lyophilized powder may be dissolved in water or in gluconic acid for injection; [0018] c) pamoate salt formulations of the active compounds in concentrations of 10 mg/1 mL to 30 mg/1 mL, preferably 15 mg/1 mL, where the lyophilized powder may be dissolved in water or in gluconic acid for injection. [0019] Suitable excipients and dosage forms are, for example, described by K. H. Bauer, K.-H. Frömming and C. Führer, Lehrbuch der Pharmazeutischen Technologie, 6 th edition, Stuttgart 1999, pages 163-186 (excipients) and pages 227-386 (dosage forms). This publication, including the references as cited therein, are hereby incorporated by reference. [0020] The LHRH antagonist can be administered via subcutaneous, oral, intramuscular or inhalative routes. EXAMPLE [0021] The disease as mentioned may be treated in accordance with the following example. A single dose of 30-60 mg per month of cetrorelix is administered by injection. The treatment is administered once a month. In another embodiment the treatment is continued for two months or lasts several months after the administration of the single dose.

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (1)

    Publication numberPublication dateAssigneeTitle
    US-3135743-AJune 02, 1964Sterling Drug IncSteroido[2. 3-d]isoxazoles and preparation thereof

NO-Patent Citations (0)

    Title

Cited By (21)

    Publication numberPublication dateAssigneeTitle
    EP-1827468-A2September 05, 2007Voyager Pharmaceutical CorporationLeuprolidacetat und acetylcholinesterase-hemmer oder nmda-rezeptorantagonisten zur behandlung von alzheimer-krankheit
    EP-1827468-A4August 05, 2009Voyager Pharmaceutical CorpLeuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer's disease
    EP-2425845-A1March 07, 2012Voyager Pharmaceutical CorporationAcetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
    EP-2425846-A1March 07, 2012Voyager Pharmaceutical CorporationInhibiteurs de acetylcholinesterase et leuprolide acetate pour le traitement de la maladie d'Alzheimer
    EP-2535336-A1December 19, 2012Abbott GmbH & Co. KG, Abbott LaboratoriesHeterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
    US-2002099018-A1July 25, 2002Jurgen Engel, Burkhard Wichert, Dieter Sauerbier, Thomas ReissmannOligopeptide lyophilisate, their preparation and use
    US-2004142942-A1July 22, 2004Yun-Fei Zhu, Wilcoxen Keith M., Struthers R. Scott, Chen Chen, Connors Patrick J., Yinghong Gao, Tucci Fabio C.Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
    US-2008171736-A1July 17, 2008Gregory Christopher W, Smith Patrick STreatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
    US-2009181964-A1July 16, 2009Astellas Pharma Inc.Propane-1,3-Dione Derivative or Salt Thereof
    US-2010173946-A1July 08, 2010Astellas Pharma IncBenzimidazolylidene propane-1,3-dione derivative or salt thereof
    US-2010324042-A1December 23, 2010Abbott Gmbh & Co. Kg.Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
    US-6716817-B1April 06, 2004Zentaris AgMethod of treatment of female infertility
    US-6828415-B2December 07, 2004Zentaris GmbhOligopeptide lyophilisate, their preparation and use
    US-7709519-B2May 04, 2010Astellas Pharma Inc.Benzimidazolylidene propane-1,3 dione derivative or salt thereof
    US-7960562-B2June 14, 2011Astellas Pharma Inc.Propane-1,3-dione derivative or salt thereof
    US-8076367-B2December 13, 2011Astellas Pharma Inc.Benzimidazolylidene propane-1,3-dione derivative or salt thereof
    US-8642598-B2February 04, 2014Abbvie Inc., AbbVie Deutschland GmbH & Co. KGHeterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
    US-9540370-B2January 10, 2017Abbvie Deutschland Gmbh & Co., Kg.Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
    US-9856234-B2January 02, 2018AbbVie Deutschland GmbH & Co. KG, Abbvie Inc.Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
    WO-2008046919-A2April 24, 2008Abbott Gmbh & Co. Kg, Abbott LaboratoriesHeterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
    WO-2008046919-A3September 25, 2008Abbott Gmbh & Co Kg, Sean Colm Turner, Margaretha Henrica Mari Bakker, Kent D StewartComposés hétérocycliques et leur utilisation comme inhibiteurs de la glycogène synthase kinase 3